Mo LC, Piao SZ, Zheng HH, Hong T, Feng Q, Ke M. Pelvic lipomatosis with cystitis glandularis managed with cyclooxygenase-2 inhibitor: A case report. World J Clin Cases 2021; 9(17): 4373-4380 [PMID: 34141803 DOI: 10.12998/wjcc.v9.i17.4373]
Corresponding Author of This Article
Mang Ke, MD, Doctor, Professor, Department of Urology, Taizhou Hospital of Zhejiang Province Affiliated with Wenzhou Medical University, No. 150 Ximen Street, Taizhou 317000, Zhejiang Province, China. kem@enzemed.com
Research Domain of This Article
Urology & Nephrology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jun 16, 2021; 9(17): 4373-4380 Published online Jun 16, 2021. doi: 10.12998/wjcc.v9.i17.4373
Pelvic lipomatosis with cystitis glandularis managed with cyclooxygenase-2 inhibitor: A case report
Li-Cai Mo, Song-Zhe Piao, Hai-Hong Zheng, Tao Hong, Qin Feng, Mang Ke
Li-Cai Mo, Song-Zhe Piao, Tao Hong, Qin Feng, Mang Ke, Department of Urology, Taizhou Hospital of Zhejiang Province Affiliated with Wenzhou Medical University, Taizhou 317000, Zhejiang Province, China
Hai-Hong Zheng, Department of Pathology, Taizhou Hospital of Zhejiang Province Affiliated with Wenzhou Medical University, Taizhou 317000, Zhejiang Province, China
Author contributions: Piao SZ designed the study; Mo LC and Piao SZ reviewed the literature and drafted the manuscript and contributed equally to this work as co-first authors; Zheng HH performed the histopathological and immunohistochemistry analyses; Hong T participated in the data tracking and analysis; Feng Q was responsible for language revision and reviewed the literature; Ke M revised the manuscript; all authors have read and approved the final manuscript.
Supported byThe Grant from the Medical Science and Technology Project of Zhejiang Province, No. 2020KY354.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no competing interests to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mang Ke, MD, Doctor, Professor, Department of Urology, Taizhou Hospital of Zhejiang Province Affiliated with Wenzhou Medical University, No. 150 Ximen Street, Taizhou 317000, Zhejiang Province, China. kem@enzemed.com
Received: February 4, 2021 Peer-review started: February 4, 2021 First decision: March 7, 2021 Revised: March 10, 2021 Accepted: April 8, 2021 Article in press: April 8, 2021 Published online: June 16, 2021 Processing time: 110 Days and 20 Hours
Abstract
BACKGROUND
Pelvic lipomatosis (PL) is a rare benign condition with characteristic overgrowth of histologically benign fat and invasion and compression of pelvic organs, often leading to non-specific lower urinary tract symptoms (LUTS). Approximately 40% of patients with PL have cystitis glandularis (CG). The cause of PL combined with CG is poorly understood, and there is currently no effective treatment. Refractory CG with upper urinary tract obstruction even requires partial or radical bladder resection.
CASE SUMMARY
In this case, a patient suffering from PL with CG was treated by transurethral resection of bladder tumour (TUR-BT) and oral administration of celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor. The LUTS were alleviated, and the cystoscopy results improved significantly. Immunohistochemistry showed up-regulated COX-2 expression in the epithelium of TUR-BT samples, suggesting that COX-2 may participate in the pathophysiological process of PL combined with CG.
CONCLUSION
We report for the first time that celecoxib may be an effective treatment strategy for PL combined with refractory CG.
Core Tip: Pelvic lipomatosis (PL) is a rare benign condition with characteristic overgrowth of histologically benign fat and invasion and compression of pelvic organs. The cause of PL with cystitis glandularis (CG) is poorly understood, and there is no effective treatment. This paper reports a patient suffering from PL with CG who was treated by transurethral resection of bladder tumour and oral administration of celecoxib. The lower urinary tract symptoms were alleviated, and the cystoscopy results improved significantly. We report for the first time that celecoxib may be an effective treatment strategy for PL combined with refractory CG.
